The Manila Times

Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

This recommendation represents an important step towards improving access for Canadians living with rare kidney diseases ...